On March 28, 2018 Tusk Therapeutics, an immuno-oncology company focused on developing immune-modulating therapeutics by targeting immune cells in cancer, reported that it will deliver an oral presentation and three poster presentations at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, Chicago, Illinois, US (Press release, Tusk Therapeutics, MAR 27, 2018, View Source [SID1234525041]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Sergio Quezada, Group Leader and Cancer Research UK Senior Research Fellow at The UCL Cancer Institute, and Chairman of Tusk Therapeutics’ Scientific Advisory Board, will deliver the oral presentation at 10.30am on Monday 16th April. The presentation will focus on Tusk Therapeutics’ first-in-class anti-CD25 antibody programme which is built on novel biology discovered by Tusk Therapeutics in collaboration with Dr. Quezada and his team at University College London. Tusk Therapeutics, Cancer Research UK (via its Commercial Partnerships Team) and UCL announced in 2017, an exclusive licensing and collaboration deal to develop and commercialise antibody-based therapeutics against CD25.
Commenting on the presentations, Luc Dochez, Chief Executive Officer of Tusk Therapeutics said: "We are excited to be presenting data at the upcoming AACR (Free AACR Whitepaper) meeting, in particular, to share data on the unique mechanism behind our anti-CD25 programme. It is well accepted that regulatory T-cells play an important role in immune-suppression in cancer but, thus far, nobody has been able to target Tregs effectively. Based on the pre-clinical proof-of-concept data generated in collaboration with Cancer Research UK and University College London, we
have shown that our novel approach can successfully target Tregs and therefore we believe that Tusk Therapeutics’ anti-CD25 antibody could become an important player in the immuno-oncology field."
The full list of abstracts accepted for presentation at this year’s AACR (Free AACR Whitepaper) Meeting are detailed below:
Oral Presentation
Title: Targeting regulatory T cells for therapeutic gain: Means and mechanisms
Presenter: Dr. Sergio A. Quezada. University College London Cancer Institute
Session: In Vivo Monitoring of Immunotherapy Responses
Date & Time: April 16, 2018, 10:30 AM – 10:55 AM
Location: N Hall C – McCormick Place North (Level 1)
Poster Presentations
Title: Generation of first-in-class anti-CD25 antibodies depleting Treg without interfering with IL2 signalling for cancer therapies
Abstract: 2787
Session: Therapeutic Antibodies, Including Engineered Antibodies 2
Date & Time: April 16, 2018, 1:00 PM – 5:00 PM
Location: Section 34
Title: A novel approach to deplete Treg cells using non-IL-2 blocking anti-CD25-targeting antibodies leads to complete rejection of established tumors
Abstract: 3143
Session: Immune Cells in the Microenvironment
Date & Time: April 17, 2018, 8:00 AM – 12:00 PM
Location: Section 5
Title: A best in class anti-CD38 antibody with antitumor and immune-modulatory properties
Abstract: 3812
Session: Therapeutic Antibodies, Including Engineered Antibodies 3
Date & Time: Apr. 17, 2018, 8:00 AM – 12:00 PM
Location: Section 34
Full abstracts are available online at www.aacr.org.
For further information, please contact:
Tusk Therapeutics
Luc Dochez, Chief Executive Officer
Media Enquiries:
Consilium Strategic Communications
Julia Wilson, Lindsey Neville
+44 (0) 203 709 5708